Found 21 articles for: "Melanoma"
Metformin Use and Risk of Non-Melanoma Skin Cancer: A Propensity-Matched Case-Control Study
December 2024 | Volume 23 | Issue 12 | Original Article | 1089 | Copyright © December 2024
Background: There is literature that suggests metformin may play a protective role against the development of non-melanoma skin cancers. Given the significant burden of disease n...
Read MoreMohs Micrographic Surgery for the Treatment of Lentigo Maligna and Lentigo Maligna Melanoma: An Outcomes Study
December 2024 | Volume 23 | Issue 12 | Original Article | 1094 | Copyright © December 2024
Background: Lentigo maligna (LM), a type of melanoma in situ (MIS), usually develops on sun-damaged skin in the elderly. If left untreated, it may advance to the point of dermal ...
Read MoreAdvances in Technology for Melanoma Diagnosis and Prognosis: An Expert Consensus Panel
September 2024 | Volume 23 | Issue 9 | Original Article | 774 | Copyright © September 2024
Background: Cutaneous melanoma (CM) is associated with a higher mortality rate than most other skin cancers. The purpose of this expert consensus panel was to review the publishe...
Read MoreCase Series of Acral and Mucosal Melanoma in a Diverse Patient Population
August 2024 | Volume 23 | Issue 8 | Case Reports | 683 | Copyright © August 2024
Melanomas affecting acral and mucosal sites have distinct features and are associated with poorer prognosis. Patients of color may be disproportionately affected. Herein we discuss six ethnically...
Read MoreUnderstanding the Association Between Social Determinants of Health and Receipt of Immunotherapy for Melanoma
May 2024 | Volume 23 | Issue 5 | Original Article | 311 | Copyright © May 2024
Purpose: In this review article, we sought to elucidate how the social determinants of health, including socioeconomic status, education, neighborhood or physical environment, ac...
Read MoreInfluence of Anatomic Locations of T1b Melanomas and Patient Age on Outcomes
May 2024 | Volume 23 | Issue 5 | Original Article | 306 | Copyright © May 2024
Background: There are no guidelines on when to more strongly recommend sentinel lymph node biopsy (SLNB) for T1b melanomas.
Objective: To examine whether a...
Read MoreBeyond the Label: Real-World Side Effects Experienced With FDA-Approved Drugs for Non-Melanoma Skin Cancers
May 2024 | Volume 23 | Issue 5 | Original Article | 301 | Copyright © May 2024
With immunotherapy historically focused on cutaneous melanoma, there has been a new wave of systemic medications available for treating non-melanoma skin cancers including basal cell carcinoma (B...
Read MoreThe Gastrointestinal Microbiome and Immune Checkpoint Inhibitors: A Review of Human Interventional Studies Among Melanoma Patients
February 2024 | Volume 23 | Issue 2 | Original Article | 78 | Copyright © February 2024
Immune checkpoint inhibitors (ICI) are widely utilized for the treatment of malignant melanoma. Interestingly, gastrointestinal microbiome composition has emerged as a predictive biomarker of imm...
Read MoreCheckpoint Inhibitor-Induced Neurotoxicity in a Case of Metastatic Melanoma
December 2023 | Volume 22 | Issue 12 | Case Reports | e25 | Copyright © December 2023
Checkpoint inhibitors (CPIs) are increasingly being used in the treatment of malignant melanoma. While showing promise in metastatic melanoma treatment, CPIs are associated with immune-related ad...
Read MoreFractional Laser for Prevention of Non-melanoma Skin Cancer
September 2023 | Volume 22 | Issue 9 | Features | 953 | Copyright © September 2023
Citation: McCormick ET, Desai S, Nelson K, et al. Fractional laser for prevention of non-melanoma skin cancer. J Drugs Dermatol. 2023;22(9):953-954. doi:10.36849/JDD.2023.NVRN0923...
Read MoreAssessing the Efficacy of Imiquimod Use in Patients With Persistent Locally Advanced Melanoma In Situ
May 2023 | Volume 22 | Issue 5 | Original Article | 457 | Copyright © May 2023
Background: The standard of care when treating melanoma in situ (MMIS) is an excision with at least 5 mm surgical margins.1 Some studies have suggested up to 9 mm margins to maxi...
Read MoreClinical Utility of Dermoscopy and 31-Gene Expression Profiling by Dermatology Providers in Melanoma Management Care
December 2022 | Volume 21 | Issue 12 | Original Article | 1347 | Copyright © December 2022
Objective: A 31-gene expression profile (31-GEP) test that predicts metastatic risk in patients with cutaneous malignant melanoma (CMM) has previously been validated and is available ...
Read MoreRecent Advances in Melanoma Tumorigenesis
December 2022 | Volume 21 | Issue 12 | Original Article | 1289 | Copyright © December 2022
Melanoma is a tumor that continues to increase in both the number of cases presenting and mortality. Patients with disease that has spread beyond the cutaneous boundary still suffer from significant m...
Read MoreAddressing Disparities in Melanoma Recognition in Skin of Color
July 2022 | Volume 21 | Issue 7 | Features | 789 | Copyright © July 2022
Melanoma is the third most common skin malignancy across all racial groups in the United States.1 While non-Hispanic white patients comprise the overwhelming majority of cases, morbidity an...
Read MoreCritical Review of the Sentinel Lymph Node Surgery in Malignant Melanoma
May 2022 | Volume 21 | Issue 5 | Original Article | 510 | Copyright © May 2022
Malignant melanoma is one of the most aggressive solid tumors but has low morbidity if treated at an early stage. Over the past decade, the advent of targeted therapy and immunotherapy have productive...
Read MoreDelayed Metastatic Polypoid Nodular Melanoma Diagnosis During COVID-19 Pandemic, Successful Treatment With Surgery and Nivolumab
December 2021 | Volume 20 | Issue 12 | Case Reports | 1343 | Copyright © December 2021
Patients with polypoid (pedunculated) melanoma have the poorest 5-year survival rate compared with all other variants of nodular melanoma, presenting with increased thickness, incidence of metastasis,...
Read MoreNovel Treatment of In-Transit Metastatic Melanoma With Shave Excision, Electrodesiccation and Curettage, and Topical Imiquimod 5% Cream
May 2021 | Volume 20 | Issue 5 | Case Reports | 555 | Copyright © May 2021
In-transit metastatic melanoma is classified as a regional intralymphatic metastasis of melanoma. Currently, there is no standardized regimen used to treat in-transit metastatic melanoma, and therapy ...
Read MoreUsing 31-Gene Expression Profile in Melanoma Risk Prognosis
May 2021 | Volume 20 | Issue 5 | Editorials | 585 | Copyright © May 2021
The Potential Efficacy of β-Blockers on Melanoma Survival: A Narrative Review
April 2021 | Volume 20 | Issue 4 | Original Article | 380 | Copyright © April 2021
Melanoma is a common tumor accounting for around 3–5% of all cutaneous malignancies with worldwide increasing incidence. It is still associated with significant mortality despite the breakthroug...
Read MoreGenomic Atypia of Lesions Clinically Suspicious for Melanoma Is Confined to Lesional Tissue Within Narrow Margins
April 2021 | Volume 20 | Issue 4 | Features | 480 | Copyright © April 2021
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
